Skip to main content

Table 1 Patient demographics and comparison of baseline characteristics of patients

From: Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization

  All cohort (n = 83) IL6 low (n = 35) IL6 high (n = 48) p IL8 low (n = 45) IL8 high (n = 38) p
Gender (male) 77 (92.7) 34 (97.1) 43 (89.5) 0.393 42 (93.3) 35 (92.1)  > 0.999
Age (≥ 65 years) 42 (50.6) 18 (51.4) 24 (50.0)  > 0.999 24 (53.3) 18 (47.3) 0.588
Race (White) 74 (89.1) 32 (91.4) 42 (87.5) 0.727 41 (91.1) 33 (86.8) 0.725
ECOG        
 0 58 (69.8) 28 (80.0) 30 (62.5) 0.111 35 (77.8) 23 (60.5) 0.122
 1 24 (28.9) 7 (20.0) 17 (35.4)   10 (22.2) 14 (36.8)  
 Missing 1 (1.2)   1 (2.1)    1 (2.6)  
Liver cirrhosis (yes) 70 (84.3) 26 (74.2) 44 (91.6) 0.065 34 (75.5) 36 (94.7) 0.03
HCC etiology        
 Hepatitis B 4 (4.8) 2 (5.7) 2 (4.1)  > 0.999 3 (6.6) 1 (2.6) 0.621
 Hepatitis C 19 (22.8) 6 (17.1) 13 (27.0) 0.287 10 (22.2) 9 (23.6) 0.874
 Alcohol 44 (53) 15 (42.8) 29 (60.4) 0.113 18 (40) 26 (68.4) 0.009
Previous TACE 18 (15.6) 9 (25.7) 9 (18.7) 0.447 11 (24.4) 7 (18.4) 0.507
Diffuse disease (≥ 10 lesion) 48 (49.3) 20 (57.1) 28 (58.3) 0.913 22 (48.8) 26 (68.4) 0.072
Median (mean) target lesion size, mm 68 (72.4) 66 (74.2) 70 (69.8) 0.65 56 (65.8) 73.5 (80.1) 0.13
Portal vein infiltration 31 (37.3) 9 (25.7) 22 (45.8) 0.061 11 (24.4) 20 (52.6) 0.008
Extrahepatic spread 21 (25.3) 6 (17.1) 15 (31.2) 0.144 11 (24.4) 10 (26.3) 0.845
Child–Pugh        
 A 77 (92.7) 34 (97.1) 43 (89.5) 0.393 44 (97.7) 33 (86.8) 0.088
 B 6 (7.2) 1 (2.8) 5 (10.4)   1 (2.2) 5 (13.1)  
BCLC        
 B 26 (31.3) 15 (42.8) 11 (22.9) 0.053 16 (35.6) 10 (26.3) 0.365
 C 57 (68.6) 20 (57.1) 37 (77.0)   29 (64.4) 28 (73.6)  
Up-to-7 criteria (outside) 71 (85.5) 29 (82.8) 42 (87.5) 0.552 37 (82.2) 34 (89.4) 0.532
Total bilirubin ≥ 17 µmol/L 25 (30.1) 6 (17.1) 19 (39.5) 0.027 11 (24.4) 14 (36.8) 0.22
Albumin < 36 g/L 20 (24.1) 3 (8.5) 17 (35.4) 0.004 7 (15.5) 13 (34.2) 0.054
AFP ≥ 400 29 (34.9) 11 (31.4) 18 (37.5) 0.519 13 (28.8) 16 (42.1) 0.235
mALBI grade (2b and 3) 21 (25.3) 3 (8.5) 18 (37.5) 0.002 8 (17.7) 13 (34.2) 0.129
  1. Bold type indicates statistical significance;
  2. IL, interleukin; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; mALBI, modified albumin–bilirubin; TACE, transarterial chemoembolization; BCLC, Barcelona Clinic Liver Cancer; AFP, alfa fetoprotein